Bristol-Myers Squibb Canada Co. announced last Friday the company reached an agreement with the pan-Canadian Pharmaceutical Alliance for the immuno-oncology treatment Opdivo, or nivolumab, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
